Icatibant Genus Pharmaceuticals

Icatibant, the active ingredient in Icatibant Genus Pharmaceuticals, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency and provides rapid relief of swelling episodes associated with the disease.

GNH USA supplies Icatibant Genus Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics, including emergency departments and specialized treatment centres, worldwide.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

- Hereditary angioedema (HAE) with C1‑inhibitor deficiency: provides rapid reduction of swelling during acute attacks. - Hereditary angioedema type I: alleviates edema during episodes. - Hereditary angioedema type II: blocks bradykinin‑mediated vascular leakage in attacks.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Infection at injection site: signs of local infection. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures. - Pregnancy: safety unknown; avoid unless the potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh benefits against possible risks. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for angioedema. - Hypersensitivity: discontinue if a severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect bradykinin pathways or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effects may raise angioedema risk. - Other bradykinin B2 antagonists: duplication of pharmacologic effect. - Combined use with ARBs and ACE inhibitors: heightened bradykinin activity.

Moderate Interactions (Monitor Closely): - Diuretics: may influence fluid status and blood pressure. - NSAIDs: could increase local injection‑site irritation. - Antihistamines: may mask early signs of hypersensitivity reactions.